Skip to content
value.today
Silverback Therapeutics, Inc. logo

Silverback Therapeutics, Inc.

Total raised
$139 M
4 rounds on record
Latest round
$85 M
Sep 2020
First round on record
Apr 2016
Today
Went public
See the company page

Silverback Therapeutics, Inc. is listed today as ARS Pharmaceuticals, Inc.: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Silverback Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2020$85 MNo. 4$50 to $250 million

Silverback Therapeutics, Inc.: Raise no. 4, Sep 2020

Investors in this round

31 investors had bought by the notice of Oct 6, 2020: 31 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Silverback Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$85 M of $85 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Laura Shawver · Executive Officer, Director
  • Jonathan L. Root · Director
  • Peter A. Thompson · Director
  • Robert L. Hershberg · Director
  • Saqib L. Islam · Director
  • Scott L. Platshon · Director
  • Thilo L. Schroeder · Director
  • Vickie L. Capps · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jill Fishbein, Secretary. Source: SEC Form D, newest notice filed Oct 6, 2020. Read the notice at the SEC.

equitySEC
Mar 2020$32 MNo. 3$10 to $50 million

Silverback Therapeutics, Inc.: Raise no. 3, Mar 2020

Investors in this round

16 investors had bought by the notice of Mar 19, 2020: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Silverback Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$32 M of $79 M offered; $47 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Peter Thompson · Executive Officer, Director
  • Jonathan Root · Director
  • Robert Hershberg · Director
  • Saqib Islam · Director
  • Thilo Schroeder · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jill E. Fishbein, Secretary. Source: SEC Form D, newest notice filed Mar 19, 2020. Read the notice at the SEC.

equitySEC
Sep 2018$13 MNo. 2$10 to $50 million

Silverback Therapeutics, Inc.: Raise no. 2, Sep 2018

Investors in this round

3 investors had bought by the notice of Sep 20, 2018: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Silverback Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$13 M of $20 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Peter A. Thompson · Executive Officer, Director
  • Robert A. Hershberg · Director
  • Saqib A. Islam · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jill Fishbein, Secretary. Source: SEC Form D, newest notice filed Sep 20, 2018. Read the notice at the SEC.

equitySEC
Apr 2016$10 MNo. 1$10 to $50 million

Silverback Therapeutics, Inc.: Raise no. 1, Apr 2016

Investors in this round

1 investor had bought by the notice of Feb 6, 2017: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Silverback Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $60 M offered; $50 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Peter A. Thompson · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jill E. Fishbein, Secretary. Source: SEC Form D and 1 amendment, newest notice filed Feb 6, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company ARS Pharmaceuticals, Inc., its revenue in fiscal 2025 came from these product and service lines: Revenue under collaboration agreements $9.72 million (12%), Revenue under supply agreements $2.37 million (3%).

    Annual report (SEC XBRL) · Dec 2025

  • Silverback Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2020).

    SEC Form D · Oct 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2020

Products and services#

No products or services of Silverback Therapeutics, Inc. are on record.

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in Silverback Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Alexandria Venture Investments, LLCVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2020)SEC Form 3
OrbiMed Capital GP VI LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2020)SEC Form 3
Presidio Management Group XII, L.L.C.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
U.S. Venture Partners XII-A, L.P.Venture capitalnot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
U.S. Venture Partners XII, L.P.Venture capitalnot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 31 investors.

Largest shareholders today

Institutions holding ARS Pharmaceuticals, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Silverback Therapeutics, Inc.
NameRoleNamed in
Laura ShawverExecutive officerOct 2020
Peter ThompsonExecutive officerMar 2020
Peter A. ThompsonExecutive officerSep 2018
Jonathan L. RootDirectorOct 2020
Laura ShawverDirectorOct 2020
Peter A. ThompsonDirectorOct 2020
Robert L. HershbergDirectorOct 2020
Saqib L. IslamDirectorOct 2020
Scott L. PlatshonDirectorOct 2020
Thilo L. SchroederDirectorOct 2020
Vickie L. CappsDirectorOct 2020
Jonathan RootDirectorMar 2020
Peter ThompsonDirectorMar 2020
Robert HershbergDirectorMar 2020
Saqib IslamDirectorMar 2020
Thilo SchroederDirectorMar 2020
Robert A. HershbergDirectorSep 2018
Saqib A. IslamDirectorSep 2018

About

Biotech company.

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.